香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 董事長 李革博士 香港，2025年4月29日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及冷雪松先生。 * 僅供識別 FANGDA PARTNERS http://www.fangdalaw.com 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 中国北京市朝阳区光华路一号 电子邮件 E-mail: email@fangdalaw.com 北 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 2025 年 4 月 29 日，无锡药明康德新药开发股份有限公司（以下简称"本公 司"或"公司"）召开 2024 年年度股东大会、2025 年第一次 A 股类别股东会议 及 2025 年第一次 H 股类别股东会议，审议通过了《关于给予董事会回购公司 A 股和/或 H 股股份一般性授权的议案》，授权董事会按照所适用的法律法规和/或 规定行使公司全部权力，在有关期间回购公司 A 股和/或 H 股总面值不超过该议 案经股东大会、A 股及 H 股类别股 ...

茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年4月29日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、胡正國先生、楊青博士及 張朝暉先生；非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、 張新博士、詹智玲女士及冷雪松先生。 * 僅供識別 证券代码：603259 证券简称：药明康德 公告编号：临 2025-032 无锡药明康德新药开发股份有限公司 2024年年度股东大会、2025 年第一次 A 股类别股东会 议及 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 第 2 頁 共 8 頁 v 1.3.0 | 7). | 購回股份(或其他證券)但沒有註銷 | 347,756 | 0.01 % | RMB | 57.53 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年4月8日刊發的公告。 | | | | | | | 於2025年4月28日，本公司實施2025年第二次股份回購，并回購 | | | | | | | 347,756股A股股份。 | | | | | | | 變動日期 2025年4月28日 | | | | | | 8). | 購回股份(或其他證券)但沒有註銷 | 329,400 | 0.01 % | RMB | 60.74 | | | 茲提述本公司於2025年4月8日刊發的公告。 | | | | | | | 於2025年4月29日，本公司實施2025年第二次股份回購，并回購 | | | | | | | 329,400股A股股份。 | | | | | | ...

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 22,008.11 points, up 0.16% or 36.15 points, with a total turnover of HKD 1,776.58 million [1] - The Hang Seng Tech Index rose by 0.62% to 5,019.73 points, while the Hang Seng China Enterprises Index fell by 0.15% to 8,067.94 points [1] Blue Chip Performance - WuXi AppTec (02359) saw a significant increase of 4.21%, closing at HKD 60.65, contributing 1.39 points to the Hang Seng Index. The company reported a revenue of approximately HKD 9.655 billion for Q1, a year-on-year increase of 20.96%, and a net profit of approximately HKD 3.672 billion, up 89.06% [2] - Other notable blue chips included Alibaba Health (00241) up 7.16%, Geely Automobile (00175) up 4.18%, while Techtronic Industries (00669) and CNOOC (00883) saw declines of 2.35% and 1.53% respectively [2] Sector Highlights - Large tech stocks mostly rose, with Meituan up 2.88% and JD.com up 1.9%, while Tencent fell over 1% [3] - Consumer stocks showed strong performance, with MaoGeping up nearly 9% and Nayuki Tea rising over 8%. The report indicated that new consumption trends are driving brand upgrades and market growth [3] - The tea beverage brand HuShang Ayi began its IPO process, with a subscription amount reaching HKD 10.298 billion and a subscription multiple of 377.51 times [4] Automotive Sector - Automotive stocks generally rose, with Li Auto (09863) up 8.08% and NIO (09866) up 4.91%. The U.S. President announced measures to reduce the impact of auto tariffs, which may benefit the sector [5][4] - The report noted that the penetration rate of new energy vehicles reached 53.3%, indicating strong growth in the automotive market [5] Biopharmaceutical Sector - Biopharmaceutical stocks performed well, with Yunnan Baiyao (01952) up 9.75% and Lepu Biopharma (02157) up 8.49%. The upcoming AACR and ASCO meetings are expected to catalyze further growth in the innovative drug sector [6] Notable Stock Movements - Yao Cai Securities (01428) surged by 31.53% following an announcement of a significant acquisition by Ant Group [7] - Horizon Robotics (09660) rose by 13.71%, with projections indicating substantial revenue growth driven by advancements in autonomous driving technology [8] - HSBC Holdings (00005) saw a mild increase of 3.03%, with plans for a share buyback of up to USD 3 billion [9] - Qingdao Beer (00168) fell by 4.07% despite reporting a revenue increase of 2.91% for Q1 [10]

Financial Data and Key Metrics Changes - In Q1 2025, revenue from continuing operations grew 23.1% year over year to RMB 9.39 billion, while total revenue reached RMB 9.65 billion, representing a 21% year over year growth [9] - Adjusted non-IFRS net profit increased 40% year over year to RMB 2.68 billion, with a record backlog for continuing operations of RMB 52.33 billion, growing 47.1% year over year [9][10] - Adjusted IFRS gross profit margin reached 41.9%, with net profit attributable to owners increasing by 89.1% year over year [25][26] Business Line Data and Key Metrics Changes - Wuxi Chemistry's CRDMO business revenue grew 32.9% year over year to RMB 7.39 billion, with adjusted non-IFRS gross profit margin improving by 4.2 percentage points to 47.5% [11][12] - Small molecule DNM business revenue grew 13.8% year over year to RMB 3.85 billion, with both Changzhou and Taishin API manufacturing sites passing FDA inspections [13] - Tides business achieved revenue of RMB 2.24 billion in Q1, representing a strong growth of 187.6% year over year [14] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 28.4% year over year, while revenue from Europe grew 26.2% year over year; however, China showed a slight decline [10] - Revenue from Wuxi Testing decreased by 4% year over year to RMB 1.29 billion, with lab testing revenue down 4.9% due to market pricing impacts [18][19] Company Strategy and Development Direction - The company will continue to focus on the CRDMO business model with an emphasis on operational efficiency and exceptional services [29] - Full year guidance remains at 10% to 15% revenue growth, targeting total revenue of RMB 41.5 billion to RMB 43 billion [30] - The company plans to accelerate global D and M capacity expansion, with CapEx expected to reach RMB 7 billion to RMB 8 billion [30] Management Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining full year guidance despite external uncertainties, emphasizing the resilience of the management team [29][30] - The company is closely monitoring changes in the global macro environment and will communicate any changes in guidance promptly [30][31] Other Important Information - The Board of Directors proposed maintaining a 30% annual cash dividend payout ratio, totaling approximately RMB 2.8 billion, along with a one-time special cash dividend of RMB 1 billion [31] - The company announced plans to repurchase and cancel RMB 1 billion worth of A shares in 2025 [32] Q&A Session Summary Question: What are the key drivers behind the robust growth in Tides? - Management indicated that the strong growth in Tides was due to both capacity ramp-up and a relatively low base from the previous year [37] Question: How does the company view the impact of tariffs on business segments? - Management acknowledged that tariffs are a systemic challenge affecting global operations, but emphasized efforts to optimize and diversify the supply chain to mitigate impacts [44][46] Question: What is the projected CapEx for 2025 and its allocation? - The projected CapEx is RMB 7 billion to RMB 8 billion, primarily focused on expanding D and M manufacturing capacity in various geographies [50][54] Question: How does the company plan to improve profit margins? - Management stated that continuous focus on operational efficiency and process development excellence will help improve margins, despite potential pressures from new capacity ramp-up [78][81]

Financial Data and Key Metrics Changes - Revenue from continuing operations grew 23.1% year over year to RMB9.39 billion, while total revenue achieved RMB9.65 billion, representing a 21% year over year growth [9] - Adjusted non-IFRS net profit grew 40% year over year to RMB2.68 billion, with a record backlog for continuing operations of RMB52.33 billion, growing 47.1% year over year [9][10] - Adjusted IFRS gross profit margin reached 41.9%, with net profit attributable to the owners of the company increasing by 89.1% year over year [26][27] Business Line Data and Key Metrics Changes - Wuxi Chemistry's CRDMO business revenue grew 32.9% year over year to RMB7.39 billion, with adjusted non-IFRS gross profit margin improving 4.2 percentage points year over year to 47.5% [11][12] - Small molecule DNM business revenue grew 13.8% year over year to RMB3.85 billion, with both Changzhou and Taishin API manufacturing sites passing FDA inspections [13] - Tides business achieved RMB2.24 billion revenue in the first quarter, representing a strong growth of 187.6% year over year [14] Market Data and Key Metrics Changes - Revenue from the U.S. market grew 28.4% year over year, while revenue from Europe grew 26.2% year over year; however, China showed a slight decline [10] - Revenue generated from clinical CRO and SMO business was down 2.2% year over year to RMB0.61 billion, attributed to market price impact [21][22] Company Strategy and Development Direction - The company will continue to focus on the CRDMO business model with an emphasis on operational efficiency and exceptional services [29] - Full year guidance is maintained, expecting revenue from continuing operations to resume double-digit growth of 10% to 15% year over year, targeting total revenue of RMB41.5 billion to RMB43 billion [30] - The company plans to accelerate global D and M capacity expansion, with CapEx expected to reach RMB7 billion to RMB8 billion [30] Management Comments on Operating Environment and Future Outlook - Management acknowledges the dynamic and complex global environment, emphasizing the need for operational resilience [29] - Despite external uncertainties, the company maintains confidence in its business model and operational capabilities [30] - The management team is committed to enhancing shareholder value through dividends and share repurchase plans [31][32] Other Important Information - The company plans to maintain a 30% annual cash dividend payout ratio of net profit, totaling approximately RMB2.8 billion, along with a one-time special cash dividend of RMB1 billion [31] - The company will repurchase and cancel RMB1 billion worth of A shares when appropriate in 2025 [32] Q&A Session Summary Question: What are the key drivers behind the robust growth in Tides? - The growth is attributed to both strong demand and capacity ramping up from a low base last year [37] Question: How does the company view the impact of tariffs on business segments? - Tariffs are seen as a systemic challenge, with less than 10% of total revenue coming from exports to the U.S. [45][46] Question: What is the expected CapEx distribution for 2025? - CapEx will focus on expanding new modality and small molecule capacities in China, Singapore, and the U.S., with over 70% allocated to D and M manufacturing capacity expansion [54] Question: How does the company plan to address pricing pressures in testing and biology segments? - The company aims to focus on contracts with higher margins and differentiation strategies to improve margins gradually [68] Question: What is the expected revenue contribution from late-stage D and M projects? - Specific numbers are difficult to provide, but the company expects sustained growth from its CRDMO business model [71]

Core Viewpoint - Nomura maintains a target price of HKD 84.59 and a "Buy" rating for WuXi AppTec (02359.HK) following strong performance in Q1 2025, with revenue and profit growth returning to double digits and a 47% year-on-year increase in order backlog [1] Financial Performance - WuXi AppTec's Q1 revenue increased by 21% year-on-year to RMB 96.5 billion, which is considered optimistic despite a low base in Q1 2024 [1] - By business segment: - Chemical business revenue reached RMB 7.39 billion, up 32.9%, driven by strong growth in TIDES business, which saw a revenue increase of 187.6% to RMB 2.24 billion [1] - Testing business sales decreased by 4.9% year-on-year to RMB 1.29 billion, reflecting ongoing pricing pressure [1] - Biological business revenue was RMB 607 million, showing an 8.2% year-on-year increase [1]

Investment Rating - The report maintains a "Buy" rating for the company [7][8] Core Views - The company reported a significant revenue growth of 20.96% year-over-year (yoy) in 1Q25, reaching 9.655 billion RMB, with a net profit increase of 89.06% yoy to 3.672 billion RMB [1] - The company expects a revenue growth acceleration in 2025-2026, driven by a strong order backlog and the performance of its TIDES business [1][2] - The TIDES segment showed remarkable growth, with a revenue increase of 187.6% yoy in 1Q25, contributing to the overall positive outlook for the company's performance [3] Summary by Sections Financial Performance - In 1Q25, the company achieved a revenue of 9.655 billion RMB, with a net profit of 3.672 billion RMB, and an adjusted non-IFRS net profit of 2.68 billion RMB, reflecting a 40.0% yoy increase [1] - The company’s order backlog reached 52.33 billion RMB in 1Q25, representing a 47.1% yoy increase [2] Business Segments - WuXi Chemistry's revenue in 1Q25 was 7.39 billion RMB, up 32.9% yoy, with a non-IFRS gross margin of 47.5% [3] - The TIDES business saw a significant increase in orders, with a backlog growth of 105.5% yoy in 1Q25 [3] Profitability and Valuation - The report forecasts net profits of 11.794 billion RMB for 2025, with a projected growth of 24.80% yoy [5] - The company’s valuation is based on a sum-of-the-parts (SOTP) approach, estimating a fair value of 269.44 billion RMB for A-shares and 278.28 billion HKD for H-shares [12]

Group 1 - The core viewpoint of the articles highlights the positive performance of the biopharmaceutical sector, particularly driven by the strong earnings report from WuXi AppTec, which reported a revenue of 9.655 billion yuan, a year-on-year increase of 20.96%, and a net profit of 3.672 billion yuan, up 89.06% [1] - The National Biopharmaceutical Index (399441.SZ) saw an increase of 0.61%, with key stocks like Kylin and WuXi AppTec rising over 6% and 5% respectively [1] - The Biopharmaceutical ETF (159859) experienced a slight increase of 0.59%, with a trading volume of 42.4373 million yuan and a total circulation size of 3.412 billion yuan, making it the largest and most liquid product in its category [1] Group 2 - The Innovation Drug Hong Kong-Shenzhen ETF (517380) rose by 0.52%, while the Medical Equipment ETF (159873) saw a slight decline [2] - Minsheng Securities indicated that the pharmaceutical sector is experiencing a sustained upward recovery, with a focus on innovative drug growth, particularly in areas such as anti-tumor, autoimmune, GLP-1, stem cells, and gene therapy [2] - Huafu Securities noted that innovative drugs are the most consensus-driven direction for increased holdings, with the pharmaceutical sector showing signs of a bottom reversal trend after four years of adjustment, making it a key area for investment [2]